Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.85 USD | +8.73% | +8.21% | -2.14% |
04-02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
03-29 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 17.74M 1.41B |
---|---|---|---|---|---|
Net income 2024 * | -40M -3.18B | Net income 2025 * | -42M -3.34B | EV / Sales 2024 * | - |
Net Debt 2024 * | 2.46M 196M | Net cash position 2025 * | 39.69M 3.16B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.62
x | P/E ratio 2025 * |
-0.55
x | Employees | 43 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.05% |
1 day | +8.73% | ||
1 week | +8.21% | ||
Current month | -14.05% | ||
1 month | -14.05% | ||
3 months | -6.04% | ||
6 months | +0.44% | ||
Current year | -2.14% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Iwicki
CEO | Chief Executive Officer | 57 | 28/02/15 |
Mary Reumuth
DFI | Director of Finance/CFO | 48 | 31/01/14 |
Todd Bazemore
PSD | President | 53 | 19/11/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Koven
BRD | Director/Board Member | 66 | 27/09/17 |
Gregory Perry
BRD | Director/Board Member | 63 | 04/03/18 |
Howard Rosen
BRD | Director/Board Member | 66 | 05/01/14 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 6.85 | +8.73% | 9,776 |
26/04/24 | 6.3 | +1.94% | 5,721 |
25/04/24 | 6.18 | -3.44% | 8,260 |
24/04/24 | 6.4 | -2.53% | 1,101 |
23/04/24 | 6.566 | +3.73% | 5,284 |
Delayed Quote Nasdaq, April 29, 2024 at 09:30 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.14% | 17.74M | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- KALA Stock